Reviewed and updated 20 August 2026 against NHS, NICE and the England Rare Diseases Action Plan 2026. This article discusses health-service access, not individual medical advice.
By Aneeta Prem MBE
People with trigeminal neuralgia often ask whether access to diagnosis and specialist care depends too much on where they live.
That is an important question. It is also one that needs better national data.
There is strong official evidence that people with rare conditions can face long diagnostic journeys, problems with care co-ordination and unequal access to specialist care. England’s 2026 Rare Diseases Action Plan now explicitly treats rare disease as a health-inequality issue.
What is much harder to find is a routinely published national TN-specific picture showing how long people wait from first presentation to diagnosis, imaging, specialist assessment or neurosurgical opinion.
Without condition-specific measurement, it is difficult to distinguish individual experience from systematic regional variation.
What national guidance already says about TN
Trigeminal neuralgia is characterised by sudden, severe facial pain, often described as electric-shock-like. Everyday actions such as touching the face, eating, talking or brushing the teeth can trigger attacks for some people.
NHS information explains that people may first see a dentist because TN can feel like tooth or jaw pain. Diagnosis involves considering other causes of facial pain, and MRI may be used as part of the investigation.
NICE referral guidance says adults with unilateral facial pain triggered by touching the affected part of the face, consistent with TN, should be referred when symptoms are refractory to treatment in line with its neuropathic-pain guidance.
So there is national clinical guidance.
The unanswered service question is how consistently and quickly the pathway works in practice.
The wider NHS recognises the diagnostic-journey problem
The England Rare Diseases Action Plan 2026 sets four long-standing priorities: faster diagnosis, greater professional awareness, better co-ordination of care and improved access to specialist care, treatment and drugs.
The plan says early findings from national work on rare-disease diagnostic journeys point to long journeys, co-ordination difficulties, limited emotional support and clear inequalities.
It also introduces a specific health-equity action intended to identify where unfair differences occur and how they can be addressed.
That policy work is broader than trigeminal neuralgia, and it should not be presented as TN-specific evidence. But the problems it describes — diagnostic delay, fragmented care, specialist access and data gaps — are highly relevant questions for TN services.
What a TN pathway dataset should show
If we want to know whether TN care is equitable, we need measures that can be compared.
A useful national dataset would ideally show:
- time from first relevant healthcare presentation to diagnosis;
- the number and type of services seen before diagnosis;
- time to MRI when imaging is clinically indicated;
- time to specialist neurology or facial-pain assessment;
- time to neurosurgical opinion where appropriate;
- geographical variation in those timelines;
- treatment changes caused by side effects or inadequate pain control; and
- patient-reported outcomes on pain, function and quality of life.
Those measures would not tell us everything. They would make variation visible enough to ask better questions.
Why dental pathways matter
TN can present in the teeth, gums or jaw, which is why dental assessment is often part of the early diagnostic journey.
The answer is not to criticise dentistry for checking common dental causes. The important point is what happens when there is no convincing dental explanation or when pain has the characteristic brief, severe, triggered pattern associated with TN.
Better cross-specialty awareness can reduce the risk of somebody circulating between dentistry, primary care and specialist services without ownership of the overall problem.
Variation is not automatically discrimination
Different hospitals and regions serve different populations, have different specialist services and face different pressures.
Variation therefore needs interpretation.
A longer wait in one area does not by itself prove discrimination. But unexplained and persistent differences in access can become a health-equity problem, particularly when patients with a rare condition have no realistic alternative pathway.
That is why measurement matters more than rhetoric.
Patient evidence has a different role
Patient surveys and support-service evidence can identify repeated experiences that routine NHS datasets may miss: dental detours, difficulty obtaining referral, medication burden, uncertainty, isolation and the effect of delays on daily life.
That evidence is valuable, but it must be labelled correctly.
A charity survey can describe the experiences of its respondents. It cannot by itself prove population prevalence or quantify geographical inequality across the whole NHS.
Patient evidence is most powerful when it identifies the questions that national service data should then test.
What better TN data would allow
Better data could show where diagnosis stalls, where referral routes work well and where specialist capacity may need strengthening.
It could also help distinguish perceived postcode variation from measurable differences in care.
That is a more useful objective than simply declaring a postcode lottery.
If the variation is real, publish it. If it is not, the data should be able to show that too.
Why this matters to me
I live with bilateral trigeminal neuralgia and, as Chief Executive of TNA UK, work with patients navigating diagnosis, treatment and specialist services.
That gives me a patient and charity-leadership perspective. It does not make me a clinician, and it does not replace clinical research.
My role is to make sure the questions patients repeatedly raise are heard clearly enough to be tested against evidence.
Final word
Health equality cannot be demonstrated by good intentions alone.
For trigeminal neuralgia, national guidance exists. What patients also need is enough transparent pathway data to know whether access to diagnosis and specialist care is working consistently across the country.
The strongest case against a postcode lottery is not a slogan. It is comparable evidence.
Sources and further reading
- Department of Health and Social Care: England Rare Diseases Action Plan 2026
- NICE: recognition and referral for facial pain
- NHS: trigeminal neuralgia
- NHS: diagnosing trigeminal neuralgia